Recent News

[News Release - PDF] CanBas' CBP501 Receives FDA Orphan Drug Designation for Malignant Mesothelioma

[News Release - PDF] CanBas Announces Last Patient Enrolled in Phase II Trial of CBP501 as First-Line Treatment of Malignant Pleural Mesothelioma

[News Release - PDF] CanBas Announces Last Patient Enrolled in Phase II Trial of CBP501 as First-Line Treatment of Non-Small Cell Lung Cancer

[News Release - PDF] CanBas' Phase II Anticancer Drug CBP501 Unique Calmodulin Binding Mechanism of Action Published in AACR Journal

[News Release - PDF] CBS9106 MoA Published in Blood - CanBas' Preclinical Anticancer Drug is a Novel Reversible Oral CRM1 Inhibitor with CRM1 Degrading Activity

[News Release - PDF] CanBas' Phase II Anti-Cancer Drug CBP501 Mechanisms Include Calmodulin Binding; CBS9106 Inhibits CRM1 [April 5, 2011].

CBP501 mechanism of action to be presented at American Association for Cancer Research (AACR) on April 4, 2011.

CBS9106 mechanism of action to be presented at American Association for Cancer Research (AACR) on April 3, 2011..

Phase I results on CBP501 published online in Clinical Cancer Research.

CanBas to present at Biotech Showcase in San Francisco on Wed., Jan. 12, 2011.

CanBas presents at BIO-Europe 2010 in Munich on November 17, 2010.

Phase II interim data on CBP501 mesothelioma trial presented at IMIG2010 by Dr. Lee M. Krug, of Memorial Sloan-Kettering Cancer Center.